Ferran Aguilar

Ferran Aguilar

Auto-generated profile, based on publicly available information

Ferran Aguilar

European Foundation for the Study of Chronic Liver Failure, Barcelona, Spain

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 April 2020 in Journal of Hepatology
Verified
Journal Article
Closed access
RMRichard Moreau
Richard Moreau
JCJoan Clària
Joan Clària
FAFerran Aguilar
Ferran Aguilar
FFFrançois Fenaille
François Fenaille
JLJuan Jose Lozano
Juan Jose Lozano
PAPaolo Angeli
Paolo Angeli

1 July 2019 in Gastroenterology
Verified
Journal Article
Open access
JFJavier Fernández
Javier Fernández
JCJoan Clària
Joan Clària
AAAlex Amorós
Alex Amorós
FAFerrán Aguilar
Ferrán Aguilar
MCMiriam Castro
Miriam Castro
VAVicente Arroyo
Vicente Arroyo
We investigated the effect of albumin treatment (20% solution) on hypoalbuminemia, cardiocirculatory dysfunction, portal hypertension, and systemic inflammation in patients with decompensated cirrhosis with and without bacterial infections. We performed a prospective study to assess the effects of long-term (12 weeks) treatment with low doses (1 g/kg body weight every 2 weeks) and high doses (1.5 g/kg every week) of albumin on serum albumin, plasma renin, cardiocirculatory function, portal pressure, and plasma levels of cytokines, collecting data from 18 patients without bacterial infections (the Pilot-PRECIOSA study). We also assessed the effect of short-term (1 week) treatment with antibiotics alone vs the combination of albumin plus antibiotics (1.5 g/kg on day 1 and 1 g/kg on day 3) on plasma levels of cytokines in biobanked samples from 78 patients with bacterial infections included in a randomized controlled trial (INFECIR-2 study). Circulatory dysfunction and systemic inflammation were extremely unstable in many patients included in the Pilot-PRECIOSA study; these patients had intense and reversible peaks in plasma levels of renin and interleukin 6. Long-term high-dose albumin, but not low-dose albumin, was associated with normalization of serum level of albumin, improved stability of the circulation and left ventricular function, and reduced plasma levels of cytokines (interleukin 6, granulocyte colony-stimulating factor, interleukin 1 receptor antagonist, and vascular endothelial growth factor) without significant changes in portal pressure. The immune-modulatory effects of albumin observed in the Pilot-PRECIOSA study were confirmed in the INFECIR-2 study. In this study, patients given albumin had significant reductions in plasma levels of cytokines. In an analysis of data from 2 trials (Pilot-PRECIOSA study and INFECIR-2 study), we found that albumin treatment reduced systemic inflammation and cardiocirculatory dysfunction in patients with decompensated cirrhosis. These effects might be responsible for the beneficial effects of albumin therapy on outcomes of patients with decompensated cirrhosis. ClinicalTrials.gov, Numbers: NCT00968695 and NCT03451292.

1 October 2020 in Journal of Hepatology
Verified
Journal Article
Closed access
CLCristina López-Vicario
Cristina López-Vicario
ACAntonio Checa
Antonio Checa
AUArantxa Urdangarin
Arantxa Urdangarin
FAFerran Aguilar
Ferran Aguilar
JAJosé Alcaraz-Quiles
José Alcaraz-Quiles
JCJoan Clària
Joan Clària

29 November 2018 in Transfusion
Verified
Journal Article
Closed access
PDF file
SJSebastian Jaramillo
Sebastian Jaramillo
MMMar Montane‐Muntane
Mar Montane‐Muntane
DCDavid Capitan
David Capitan
FAFerran Aguilar
Ferran Aguilar
TVToni Vilaseca
Toni Vilaseca
RNRicard Navarro‐Ripoll
Ricard Navarro‐Ripoll

7 March 2025 in Science Advances
Verified
Journal Article
Open access
AKAnnarein J. C. Kerbert
Annarein J. C. Kerbert
CECornelius Engelmann
Cornelius Engelmann
AHAbeba Habtesion
Abeba Habtesion
PKPavitra Kumar
Pavitra Kumar
MHMOHSIN HASSAN
MOHSIN HASSAN
RJRajiv Jalan
Rajiv Jalan
Hyperammonemia is common in liver cirrhosis and causally associated with hepatic encephalopathy development. Little is known about its hepatotoxic effects, which we aimed to characterize in this study. In a mouse model of chronic hyperammonemia without preexisting liver disease, we observed development of liver fibrogenesis and necroptotic cell death. Hyperammonemia also induced dysregulation of its main metabolic pathway, the urea cycle, as reflected by down-regulation of urea cycle enzyme protein expression and accumulation of its metabolites. Inhibition of receptor-interacting serine/threonine-protein kinase 1 (RIPK1) and its upstream inducer Toll-like receptor 4 (TLR4) protected against liver injury and further hyperammonemia. In clinically relevant rodent models of hyperammonemia (genetic ornithine transcarbamylase deficiency and bile duct ligation–induced cirrhosis), TLR4 inhibition reduced circulating ammonia. In conclusion, hyperammonemia induces liver fibrogenesis and RIPK1-mediated cell death, which is associated with urea cycle dysfunction. Inhibition of RIPK1 and TLR4 protects against hyperammonemia-induced liver injury and are potential therapeutic targets for hyperammonemia and chronic liver disease progression.

27 November 2025 in Journal of Hepatology
Verified
Journal Article
Closed access
FAFerran Aguilar
Ferran Aguilar
JLJuan Jose Lozano
Juan Jose Lozano
JCJoan Clària
Joan Clària
SGSara Noemi Reinartz Groba
Sara Noemi Reinartz Groba
MRMathis Richter
Mathis Richter
ASAmeli Schwalber
Ameli Schwalber